Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Binimetinib + Cetuximab |
Indication/Tumor Type | Cancer of Unknown Primary |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | Cancer of Unknown Primary | predicted - sensitive | Binimetinib + Cetuximab | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Mektovi (binimetinib) and Erbitux (cetuximab) resulted in a significant but brief response in all lesions in a patient with metastatic cancer of unknown primary harboring BRAF V600E (PMID: 39391046). | 39391046 |
PubMed Id | Reference Title | Details |
---|---|---|
(39391046) | Cancer of unknown primary and BRAF V600E meeting the BEACON combination: A case report. | Full reference... |